Clinical Trial Update: A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 safety and efficacy study of SAR405838 and Pimasertib in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Pimasertib (pimasertib)
• SAR405838 (SAR405838)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1 | Status: COMPLETED